Abstract
Background and Objective: Alzheimer's disease (AD) is arguably the largest healthcare issue of our time. AD is thought to be principally the result of an inter-play between the β-amyloid peptide and Tau, and it is driven by several genetic and environmental risk factors. Recent studies have shown that small non-protein-coding microRNA (miRNA) and the associated post-transcriptional gene regulation are important regulators of many neurodegenerative diseases, including AD. We reviewed recent studies identifying various miRNA dysregulated in AD. These miRNAs could play a significant role in the pathophysiology of AD, in both β-amyloid peptide and Tau toxicity.
Conclusion: The identification of dysregulated miRNAs pattern can serve as specific AD biomarkers which may provide the basis for new and effective diagnostic approach. In addition, these miRNAs may represent new targets for pharmaceutical development.
Keywords: Alzheimer disease, microRNA, β-amyloid, Tauopathy, biomarker, treatment.
Graphical Abstract
Related Journals
Current Drug Safety
Current Neuropharmacology
Current Pharmaceutical Design
Current Neurovascular Research
Current Pharmaceutical Analysis
Central Nervous System Agents in Medicinal Chemistry
Current Vascular Pharmacology
Current Alzheimer Research
Current Molecular Pharmacology
Current Aging Science
Related Books
Frontiers in Clinical Drug Research - CNS and Neurological Disorders
Frontiers in Clinical Drug Research - CNS and Neurological Disorders
New Findings from Natural Substances
Pharmaceutical Chemistry and Production: An Introductory Textbook
Evidence-Based Research in Ayurveda against COVID-19 in Compliance with Standardized Protocols and Practices
Frontiers in Clinical Drug Research - CNS and Neurological Disorders
Pharmaceuticals for Targeting Coronaviruses
Medical Applications of Beta-Glucan
Nanotechnology Driven Herbal Medicine for Burns: From Concept to Application
Frontiers in Clinical Drug Research-Dementia
46
4
1
1